Pharmacy Claims Fraud Detection

Inspector AI identifies fraud, waste, and abuse patterns in your pharmacy claims using readable, explainable detection rules, reviewing every claim instead of a sample.

The Problem: Invisible Pharmaceutical Fraud in Latin America

Health insurers in Latin America face a quiet but significant challenge: fraud and abuse in pharmaceutical claims. Unlike traditional medical fraud where false claims may be obvious, pharmaceutical fraud hides in transactions that individually appear completely legitimate. Each dispensation has a valid prescriber, an in-formulary medication, and a patient with active coverage.

The problem is that traditional authorization systems evaluate each transaction in isolation. When a patient submits the same prescription for the fourth time in six months with exactly the same medications, each individual submission passes all validations. When a pharmacist systematically dispenses the brand version when a generic is available, each dispensation is technically correct. When a patient receives medications for conditions they have never been diagnosed with, the transaction is approved because the medication is on the formulary.

These patterns only become visible when the complete history of each patient, prescriber, and pharmacy is analyzed over time. Longitudinal analysis of claims data reveals systematic behaviors that no individual transaction review could detect.

These are not random errors or normal variations in medical practice. These are repetitive, systematic patterns indicating behavioral fraud, avoidable waste, and abuse of the pharmaceutical reimbursement system. The good news is that these patterns are detectable when the right analytical tools are in place.

What We Look For: Five Categories of Anomalies

Inspector AI classifies pharmaceutical anomalies into five main categories. Each finding is explained by a readable rule and the specific dispensation data that triggered it — not by an opaque score.

Waste and utilization. This includes early refills where patients request refills before their previous supply should be exhausted, same-molecule re-authorizations indicating unnecessary duplication, and same-day dispensations suggesting medication stockpiling.

Generic substitution opportunity. Brand dispensations when a clinically equivalent generic is available. In one Latin American insurance network, 36% of dispensations were brand when a generic existed, at up to 4x the cost.

Clinical mismatch. Medications with no diagnosis supporting them, including complete therapeutic area mismatches — medications for body systems entirely different from the patient's diagnosis. In one Latin American insurance network, 1 in 4 members on chronic medication had no diagnosis supporting it. But 84% of them were genuinely chronic. We were looking for leakage; we found patients.

Behavioral fraud risk. This includes patterns such as cloned prescriptions — the exact same combination of medications resubmitted months later as if new — and cumulative doses exceeding safe limits.

Financial anomalies. Price or billing patterns that do not correspond to expected market values.

1 in 4

Members on chronic medication with no supporting diagnosis

84%

Of them were genuinely chronic

36%

Dispensations that were brand when a generic existed

How It Works: Analysis Without Initial Integration

Inspector AI is designed to demonstrate value before requiring any system integration. The process begins with a proof of concept that can be completed in just 3 weeks, with no need to connect your internal systems.

The first step is uploading a sample of your pharmacy claims data. No integration with your management system is required — simply a historical data file. Inspector AI processes this data through a set of readable detection rules, each designed to identify a specific pattern of fraud, waste, or abuse.

The analysis generates a detailed report quantifying exactly how much spend shows anomalies and of what type. These are not generic alerts — each finding is backed by specific data: identified patients, involved transactions, amounts at risk, and detected patterns.

For organizations that want to go beyond retrospective analysis, Inspector AI offers real-time integration through a FHIR PAS (Prior Authorization Support) compatible API. This allows evaluation of each pharmacy claim at the point of dispensation, before payment is approved. The platform also integrates with customer service systems like Freshdesk and call centers to efficiently manage alerts.

The platform uses an OpenAI-compatible API, facilitating integration with existing workflows and allowing technical teams to build on the detection platform without depending on proprietary interfaces.

Financial Impact: The Leakage Nobody Reviews

A US$20 claim under a US$50 review threshold never gets looked at; thousands of them are the loss ratio. Pharmaceutical leakage rarely sits in one large claim: it sits in the sum of small transactions that no sample-based review prioritizes.

In audited pharmacy data from one pilot insurer, potential leakage came to about US$26 per active pharmacy user per year. It is a reference point, not a promise: every book has its own drug mix and prescribing culture, and the only way to know your number is to measure it in your own data.

Precision matters as much as volume. In one Latin American insurance network, 8 of 9 rules evaluated showed 100% true positives on manual review. And with medical cost trend in Latin America running around 11.9% (WTW Global Medical Trends), every point of avoidable leakage counts.

Additionally, the non-financial impact is substantial: better quality of care, improved patient safety, and enhanced regulatory compliance.

Inspector AI was recognized with the International Innovation Award 2025 by the Fundacion Iberoamericana Alianza del Seguro in Monterrey, Mexico, validating the detection approach and methodology used.

~US$26

Potential leakage per active pharmacy user per year (pilot insurer)

8 of 9

Rules evaluated with 100% true positives

~11.9%

Medical cost trend in Latin America (WTW)

Why Inspector AI for Pharmacy Claims Fraud Detection

Pharmacy claims fraud detection requires a fundamentally different approach from traditional transactional authorization. Conventional systems evaluate each transaction in isolation — checking coverage, formulary, and authorization. This is necessary but insufficient.

Inspector AI complements your existing systems by providing the longitudinal analysis layer that reveals patterns invisible to transactional authorization. It does not replace your management system — it enhances it with intelligence that only emerges from data analysis over time.

The no-integration proof of concept means you can validate the platform's value in 3 weeks, with no risk or IT resource commitment. If the findings justify the investment, real-time integration via FHIR PAS allows moving from retrospective analysis to active prevention.

For health insurers in Latin America looking to reduce pharmaceutical losses in a measurable and rapid way, Inspector AI offers a clear path: demonstrate the problem with real data, quantify the financial impact, and provide the tools to resolve it.

Discover How Much You Lose to Pharmacy Fraud

Upload a sample of your claims data and receive a detailed anomaly report in 3 weeks. No system integration, no commitment.

Request Free Analysis